Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - pramipexole dihydrochloride monohydrate, quantity: 1 mg - tablet - excipient ingredients: pregelatinised maize starch; mannitol; microcrystalline cellulose; povidone; purified talc; magnesium stearate - the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa. the symptomatic treatment of primary restless legs syndrome.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - pramipexole dihydrochloride monohydrate, quantity: 0.25 mg - tablet - excipient ingredients: pregelatinised maize starch; mannitol; microcrystalline cellulose; povidone; purified talc; magnesium stearate - the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa. the symptomatic treatment of primary restless legs syndrome.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - pramipexole dihydrochloride monohydrate, quantity: 0.125 mg - tablet - excipient ingredients: pregelatinised maize starch; mannitol; microcrystalline cellulose; povidone; purified talc; magnesium stearate - the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa. the symptomatic treatment of primary restless legs syndrome.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - sertraline hydrochloride, quantity: 111.9 mg (equivalent: sertraline, qty 100 mg) - tablet, film coated - excipient ingredients: hyprolose; sodium starch glycollate type a; titanium dioxide; polysorbate 80; microcrystalline cellulose; calcium hydrogen phosphate; macrogol 400; hypromellose; magnesium stearate - children and adolescents sertraline hydrochloride is indicated for the treatment of children (aged 6 years of age and older) and adolescents with ocd.,adults sertraline hydrochloride is indicated for the treatment of: ? major depression, obsessive compulsive disorder (ocd) and panic disorder ? social phobia (social anxiety disorder) and the prevention of its relapse ? pre-menstrual dysphoric disorder (pmdd) as defined by dsm-iv criteria

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - sertraline hydrochloride, quantity: 111.9 mg (equivalent: sertraline, qty 100 mg) - tablet, film coated - excipient ingredients: hyprolose; sodium starch glycollate type a; titanium dioxide; polysorbate 80; microcrystalline cellulose; calcium hydrogen phosphate; macrogol 400; hypromellose; magnesium stearate - children and adolescents sertraline hydrochloride is indicated for the treatment of children (aged 6 years of age and older) and adolescents with ocd.,adults sertraline hydrochloride is indicated for the treatment of: ? major depression, obsessive compulsive disorder (ocd) and panic disorder ? social phobia (social anxiety disorder) and the prevention of its relapse ? pre-menstrual dysphoric disorder (pmdd) as defined by dsm-iv criteria

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - sertraline hydrochloride, quantity: 55.95 mg (equivalent: sertraline, qty 50 mg) - tablet, film coated - excipient ingredients: macrogol 400; titanium dioxide; microcrystalline cellulose; polysorbate 80; calcium hydrogen phosphate; magnesium stearate; sodium starch glycollate type a; hyprolose; hypromellose - children and adolescents sertraline hydrochloride is indicated for the treatment of children (aged 6 years of age and older) and adolescents with ocd.,adults sertraline hydrochloride is indicated for the treatment of: ? major depression, obsessive compulsive disorder (ocd) and panic disorder ? social phobia (social anxiety disorder) and the prevention of its relapse ? pre-menstrual dysphoric disorder (pmdd) as defined by dsm-iv criteria

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - sertraline hydrochloride, quantity: 55.95 mg (equivalent: sertraline, qty 50 mg) - tablet, film coated - excipient ingredients: macrogol 400; titanium dioxide; microcrystalline cellulose; polysorbate 80; calcium hydrogen phosphate; magnesium stearate; sodium starch glycollate type a; hyprolose; hypromellose - children and adolescents sertraline hydrochloride is indicated for the treatment of children (aged 6 years of age and older) and adolescents with ocd.,adults sertraline hydrochloride is indicated for the treatment of: ? major depression, obsessive compulsive disorder (ocd) and panic disorder ? social phobia (social anxiety disorder) and the prevention of its relapse ? pre-menstrual dysphoric disorder (pmdd) as defined by dsm-iv criteria

United States - English - NLM (National Library of Medicine)

mylan specialty l.p. - selegiline (unii: 2k1v7gp655) (selegiline - unii:2k1v7gp655) - selegiline 6 mg in 24 h - emsam (selegiline transdermal system) is a monoamine oxidase inhibitor (maoi) indicated for the treatment of adults with major depressive disorder (mdd) [see clinical studies (14)] . the available data on emsam use in pregnant women are not sufficient to inform a drug-associated risk of adverse pregnancy-related outcomes. in animal embryo-fetal development studies, transdermal administration of selegiline to rats and rabbits at doses up to 60 and 64 times the maximum recommended human dose (mrhd) respectively, produced slight increases in malformations in both rats and rabbits, and decreased fetal weight, delayed ossification, and embryo-fetal post-implantation loss in rats. most of these effects were seen at the high dose in both rats and rabbits. these effects were not seen at 8 times and 16 times the mrhd in rats and rabbits, respectively. in a pre-natal and post-natal development study, transdermal administration of selegiline in rats at doses 8, 24, and 60 times mrhd produced a decrease in pup weight an

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - pramipexole dihydrochloride monohydrate, quantity: 1.5 mg - tablet - excipient ingredients: pregelatinised maize starch; mannitol; microcrystalline cellulose; povidone; purified talc; magnesium stearate - the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - pramipexole dihydrochloride monohydrate, quantity: 1 mg - tablet - excipient ingredients: pregelatinised maize starch; mannitol; microcrystalline cellulose; povidone; purified talc; magnesium stearate - the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa.,the symptomatic treatment of primary restless legs syndrome.